Immuneering (NASDAQ:IMRX) has achieved a 64% overall survival rate at 12 months in an ongoing Phase 2a clinical trial for its lead drug candidate, atebimetinib, in combination with chemotherapy for patients with metastatic pancreatic cancer.
The biotechnology firm, which reported its 2025 financial results on Friday, confirmed that median follow-up for the 34-patient study stands at 13.4 months.
Following successful alignment with the FDA and EMA, the company remains on track to initiate its pivotal Phase 3 MAPKeeper 301 study by mid-2026.
The Cambridge, Massachusetts-based company ended 2025 with a cash position of $217 million, which management expects will fund operations into early 2029.
This financial stability comes as Immuneering transitions into a late-stage clinical organization.
For the full year 2025, the company reported a net loss of $56 million, with research and development expenses totaling $42 million.
The forthcoming Phase 3 trial will evaluate atebimetinib combined with modified gemcitabine/nab-paclitaxel (mGnP) as a first-line treatment, aiming to validate the survival signals observed in the mid-stage study.